Opus Genetics president Ben Yerxa (L) and CEO George Magrath
Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder
The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints News.
Ocuphire $OCUP will acquire …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
